Wellmarker Bio
- Company typePrivate
- Founded2016
- HeadquartersSeoul, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingServices
Wellmarker Bio firmographics
Firmographics- Name
- Wellmarker Bio
- Legal name
- Wellmarker Bio
- Website
- https://wmbio.co
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Wellmarker Bio industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Translational Medicine & Biomarkers (HLAIALAF)
- akta.pro secondary industries
- Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Wellmarker Bio is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Markets served
Wellmarker Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Technology Exports: The company is engaging in technology exports as part of its revenue strategy, indicating a technology licensing model for its drug development intellectual property.
Go-to-market motion1 record
Wellmarker Bio product offering
Product offeringCore offering
Wellmarker Bio is a South Korean biotech company that develops novel anticancer drugs. The company conducts clinical trials for its therapeutic candidates (including trials run in Australia), plans preclinical and Investigational New Drug (IND) submissions for new drug candidates, and engages in technology exports and licensing of its drug development intellectual property to pharmaceutical partners.
Differentiator
Problem solved
Functional benefit
Products and services
- Anticancer Drug Development Program
Quantifiable outcome
- Successfully completed Series C funding round raising approximately 14 billion won
- +1 more outcomes
Companies that use Wellmarker Bio
Customer profileSegments1 record
Ideal customer profiles2 records
Wellmarker Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Wellmarker Bio partnerships and signals
Strategic signalScale indicators1 record
Wellmarker Bio competitors and assessment
Company assessmentMarket position
Customer concentration
Wellmarker Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Wellmarker Bio leadership team
Management profileNumber of profiles
Profiles1 record
Wellmarker Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Wellmarker Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Wellmarker Bio
What does Wellmarker Bio do?
Wellmarker Bio is a South Korean biotech company that develops novel anticancer drugs. The company conducts clinical trials for its therapeutic candidates (including trials run in Australia), plans preclinical and Investigational New Drug (IND) submissions for new drug candidates, and engages in technology exports and licensing of its drug development intellectual property to pharmaceutical partners.
Is Wellmarker Bio a public or private company?
Wellmarker Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Wellmarker Bio founded?
Wellmarker Bio was founded in 2016. It employs 51 to 100 people.
Where is Wellmarker Bio based?
Wellmarker Bio is headquartered in Seoul, South Korea, in the Asia region.
How does Wellmarker Bio make money?
One revenue line is on record: technology Exports.
Does Wellmarker Bio have an API?
No public API is recorded for Wellmarker Bio.
What industry is Wellmarker Bio in?
Wellmarker Bio's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAF, Translational Medicine & Biomarkers, with a secondary code of HLAAAMAD, Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers). Its NAICS code is 541714 and its SIC code is 2834.